# Genetically Modified T Cells Treating Malignant Tumors

> **NCT06515626** · EARLY_PHASE1 · RECRUITING · sponsor: **Yi Zhang** · enrollment: 100 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **BIOLOGICAL:** CAR-T cell reinfusion

## Key facts

- **NCT ID:** NCT06515626
- **Lead sponsor:** Yi Zhang
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-18
- **Primary completion:** 2025-12
- **Final completion:** 2027-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06515626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06515626, "Genetically Modified T Cells Treating Malignant Tumors". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06515626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*